Christopher Hourigan – Wikipedia

Posted on by

From Wikipedia, the free encyclopedia

Leukemia physician scientist

Christopher Hourigan is a physician-scientist known for work on measurable residual disease (MRD; previously termed minimal residual disease) in acute myeloid leukemia.[1][2][3][4][5][6][7]

He is the Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland.[8]

Education[edit]

Hourigan graduated from Oxford University Medical School and received his DPhil for work with Sir John Bell (physician) at the Weatherall Institute of Molecular Medicine at Oxford University. He completed postdoctoral clinical training at Guy’s and St Thomas’ Hospital in London, Johns Hopkins Bayview Medical Center, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore.[8] He is ABIM board certified in Internal Medicine, Hematology, and Medical Oncology.

Research[edit]

Hourigan is best known for work on Measurable Residual Disease (MRD) and precision medicine in Acute Myeloid Leukemia (AML). This included the demonstration that intervention in patients with AML MRD may improve survival,[9][10][11][12][13][14][15][16][17]
that low-level TP53 mutations are detectable pre-transplantation in patients with sickle cell disease who develop myeloid malignancy after hematopoietic stem cell transplantation, and that patient-personalized single cell sequencing can distinguish mutations associated with non-malignant cells rather than residual AML.[18] He holds senior leadership positions in the European Leukemia Network (ELN) guidelines committee for AML MRD, the Foundation for the National Institutes of Health (fNIH) biomarkers consortium for AML MRD, the National Cancer Institute (NCI) MyeloMATCH precision medicine initiative, the Center for International Blood and Marrow Transplant Research (CIBMTR) and on the American Society of Hematology (ASH) guidelines committee for AML in older adults.

Honors and awards[edit]

In 2019, Hourigan received a Presidential Early Career Award for Scientists and Engineers for his research on Measurable Residual Disease in Acute Myeloid Leukemia.[19]

In 2020, Hourigan was awarded the National Heart, Lung, and Blood Institute Orloff Award[20] and honored for one of the top NIH accomplishments of 2020.[21]

Selected publications[edit]

  • Hourigan, C. S., Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., … & Horwitz, M. E. (2020). Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. Journal of Clinical Oncology, 38(12), 1273-1283.[22]
  • Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, The Journal of the American Society of Hematology. 2018 Mar 22;131(12):1275-91. [2]
  • Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Oct;562(7728):526-31.[3] (PMC open access)
  • Hourigan, C. S., & Karp, J. E. (2013). Minimal residual disease in acute myeloid leukaemia. Nature reviews Clinical oncology, 10(8), 460-471.[5]
  • Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017). Measurable residual disease testing in acute myeloid leukaemia. Leukemia, 31(7), 1482-1490. [6]

References[edit]

  1. ^ Search Results for author Hourigan CS on PubMed.
  2. ^ [1] Google Scholar Author page, Accessed Dec. 25, 2021
  3. ^ Schuurhuis, Gerrit J.; Heuser, Michael; Freeman, Sylvie; Béné, Marie-Christine; Buccisano, Francesco; Cloos, Jacqueline; Grimwade, David; Haferlach, Torsten; Hills, Robert K.; Hourigan, Christopher S.; Jorgensen, Jeffrey L. (2018-03-22). “Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party”. Blood. 131 (12): 1275–1291. doi:10.1182/blood-2017-09-801498. ISSN 0006-4971. PMC 5865231. PMID 29330221.
  4. ^ Tyner, Jeffrey W.; Tognon, Cristina E.; Bottomly, Daniel; Wilmot, Beth; Kurtz, Stephen E.; Savage, Samantha L.; Long, Nicola; Schultz, Anna Reister; Traer, Elie; Abel, Melissa; Agarwal, Anupriya (17 October 2018). “Functional genomic landscape of acute myeloid leukaemia”. Nature. 562 (7728): 526–531. Bibcode:2018Natur.562..526T. doi:10.1038/s41586-018-0623-z. ISSN 1476-4687. PMC 6280667. PMID 30333627.
  5. ^ a b Hourigan, Christopher S.; Karp, Judith E. (2013). “Minimal residual disease in acute myeloid leukaemia”. Nature Reviews Clinical Oncology. 10 (8): 460–471. doi:10.1038/nrclinonc.2013.100. ISSN 1759-4782. PMC 4163748. PMID 23799371.
  6. ^ a b Hourigan, C. S.; Gale, R. P.; Gormley, N. J.; Ossenkoppele, G. J.; Walter, R. B. (2017). “Measurable residual disease testing in acute myeloid leukaemia”. Leukemia. 31 (7): 1482–1490. doi:10.1038/leu.2017.113. ISSN 1476-5551. PMID 28386105. S2CID 1297753.
  7. ^ “Christopher S. Hourigan”. scholar.google.com. Retrieved 2021-11-23.
  8. ^ a b “Principal Investigators”. NIH Intramural Research Program. Retrieved 2021-11-03.
  9. ^ Hourigan, C (2020). “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia with Genomic Evidence of Residual Disease”. Journal of Clinical Oncology. European Hematology Association. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. PMC 7164487. PMID 31860405. Retrieved 26 November 2021.
  10. ^ Osterweil, Neil (2019-06-25). “MDedge Hematology News”. AML variants before transplant signal need for aggressive therapy.
  11. ^ Lovely, Brittany (2019-08-15). “OncLive”. AML Findings Suggest a Broader Role for Genomic Testing. Vol. 20, no. 16.
  12. ^ Melville, Nancy (2019-06-25). “Medscape”. Measurable Residual Disease in AML Ups Post-HSCT Relapse Risk.
  13. ^ “ecancer”. EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?. 2019-06-14.
  14. ^ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease”. Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN 0732-183X. PMC 7164487. PMID 31860405.
  15. ^ Stenger, Matthew (2020-01-17). “The ASCO Post”. Conditioning Intensity for Allogeneic Transplantation in Patients With AML. Retrieved 27 November 2021.
  16. ^ Kuznar, Wayne (2020-02-26). “MEDPAGE TODAY”. Christopher Hourigan, DM, DPhil, on Mutation-based MRD and Conditioning for AML.
  17. ^ Llobet-Canela, Marta (2020-08-26). “AML Hub”. Patients with pretransplant MRD may benefit from conditioning intensification.
  18. ^ “Mission Bio’s Tapestri Platform Used to Distinguish Acute Myeloid Leukemia Clones from CHIP Clones”. CISION PR Newswire.
  19. ^ “President Donald J. Trump Announces Recipients of the Presidential Early Career Award for Scientists and Engineers – The White House”. trumpwhitehouse.archives.gov. Retrieved 2021-11-03.
  20. ^ “NHLBI Orloff Award 2020: Chris Hourigan”. YouTube.
  21. ^ “Changing fate by personalizing treatment for a high-risk blood cancer”. 30 December 2020.
  22. ^ Hourigan, Christopher S.; Dillon, Laura W.; Gui, Gege; Logan, Brent R.; Fei, Mingwei; Ghannam, Jack; Li, Yuesheng; Licon, Abel; Alyea, Edwin P.; Bashey, Asad; Deeg, H. Joachim (2020-04-20). “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease”. Journal of Clinical Oncology. 38 (12): 1273–1283. doi:10.1200/JCO.19.03011. ISSN 0732-183X. PMC 7164487. PMID 31860405.

External links[edit]